


CLAIM AMENDMENTS

Please amend the claims as follows. This listing of claims replaces all previous listings.

1 (Currently amended) A compound ~~or a pharmaceutically acceptable salt or a stereoisomer of~~ formula I



or a pharmaceutically acceptable salt thereof

wherein


R₁ is selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, and CH₂OR₄;

R₂ is selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, heterocyclo or substituted heterocyclo, heteroaryl or substituted heteroaryl, and CH₂OR₄;

R₃ is selected from the group consisting of hydrogen, alkyl or substituted alkyl, CH₂OR₄, OR₂, SR₂, halo, NHR₂, NHCOR₄, NHCO₂R₄, NHCONR₄R₄', and NHSO₂R₄;

R₄ and R₄' for each occurrence are each independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, heterocyclo or substituted heterocyclo, and heteroaryl or substituted heteroaryl;

G is selected from the group consisting of:



wherein

R₈ is CN;

R₉, R₁₀ and R₁₁ are each independently selected from the group consisting of hydrogen (H), NO₂, CN, CF₃, OR₄, CO₂R₄, NR₄R₄', CONR₄R₄', CH₂OR₄, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, and heteroaryl or substituted heteraryl;

A to F ~~is~~ are each independently selected from N or and CR₁;

J, K, L, P and Q are each independently selected from NR₁₂, O, S, SO, SO₂, or CR₁₂R₁₂';

R₁₂ and R₁₂' in each functional group are each independently selected from a bond or R₁; ~~and~~

m is an integer of 0 or 1;

X is a linking group selected from the group consisting of NR₄ and CHR₄;

Y is selected from the group consisting of O, NR₄, NOR₄, S and CH₂;

Z is -O- or NR₄; and

n is an integer of 1 or 2;

with the following provisos:

(a) when Y is NOR₄, R₄ is not hydrogen;

(b) ~~excluding compounds where the following occur simultaneously: when R₁ is methyl;~~

X is NH₂; and

Y is O or S; and then

Z is not O;

(c) ~~when excluding compounds where the following occur simultaneously: (i) R₁ is methyl;~~

(ii) X is NH₂

Z is O;

(iii) Y is NR₄;


(iv) R₄ is selected from the group consisting of hydrogen, alkyl or substituted alkyl,

alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, arylalkyl or

substituted arylalkyl, aryl or substituted aryl, and heteroaryl or substituted heteroaryl;

and

(v) G has the following structure:



wherein

- R_{13} is selected from the group consisting of hydrogen, cyano (-CN), nitro (-NO₂), halo, heterocyclo, OR₁₄, CO₂R₁₅, CONHR₁₅, COR₁₅, S(O)_pR₁₅, SO₂NR₁₅R_{15'}, NHCOR₁₅ and NHSO₂R₁₅;
- R_{14} in each functional group is independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, CHF₂, CF₃, and COR₁₅;
- R_{15} and R_{15}' in each functional group are each independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, heterocycloalkyl or substituted heterocycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, and -CN;
- \underline{AA} and \underline{BB} are each independently selected from the group consisting of hydrogen, halo, cyano(-CN), nitro(-NO₂), alkyl or substituted alkyl, and OR₁₄; and
- p is an integer from 0 to 2;

then Z is not O.

2. (cancelled)

3 (cancelled)

4. (Currently amended) The compound as defined in claim 1, or a pharmaceutically acceptable salt thereof, wherein

R_1 is ~~hydrogen or~~ alkyl;

R_2 is hydrogen or alkyl;

R₃ is hydroxyl;

X is NR₄;

Y is O;

Z is O;

and n is 1

5. (Currently amended) A pharmaceutical composition comprising ~~the~~ a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefore.

6. (Original) The pharmaceutical composition as defined in claim 5 further comprising a growth promoting agent.

7. (Currently amended) A pharmaceutical composition comprising a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent selected from the group consisting of parathyroid hormone, bisphosphonates, estrogen, testosterone, progesterone, selective estrogen receptor modulators, growth hormone secretagogues, growth hormone, progesterone receptor modulators, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents, anti-depressants, anti-anxiety agents, anabolic agents, and thyroid mimetics.

8. (Currently amended) A method for treating prostate cancer which comprises administering to a mammalian species in need of treatment an effective amount of a compound as defined in claim 1 or a pharmaceutically acceptable salt thereof.

9.(cancelled)

10. (Currently amended) A compound selected from the group consisting of 1-(4-Cyano-2-ethyl-3-(trifluoromethyl)phenyl-1-carbamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid methyl ester or a pharmaceutically acceptable salt thereof;

1-(4-Cyanonaphthalen-1-ylcarbamoyl)-3-hydroxy-pyrrolidine-2-carboxylic acid methyl ester or
a pharmaceutically acceptable salt thereof;

1-(5-Chloro-6-cyano-pyridin-3-ylcarbamoyl)-3-hydroxypyrrolidine-2-carboxylic acid methyl
ester or a pharmaceutically acceptable salt thereof; and

1-[2-(4-Cyanonaphthalen-1-yl)acetyl]-3-hydroxypyrrolidine-2-carboxylic acid methyl ester or a
pharmaceutically acceptable salt thereof.


11. (new) A pharmaceutical composition comprising the a compound as defined in claim 10, or a
pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.

12. (new) The pharmaceutical composition as defined in claim 11 further comprising a growth
promoting agent.

13 (new) A pharmaceutical composition comprising a compound as defined in claim 10, or a
pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent selected
from the group consisting of parathyroid hormone, bisphosphonates, estrogen, testosterone,
progesterone, selective estrogen receptor modulators, growth hormone secretagogues, growth
hormone, progesterone receptor modulators, anti-diabetic agents, anti-hypertensive agents, anti-
inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides,
cholesterol lowering agents, anti-depressants, anti-anxiety agents, anabolic agents, and thyroid
mimetics.

14. (new) A method for treating prostate cancer which comprises administering to a mammalian
species in need of treatment an effective amount of a compound as defined in claim 10 or a
pharmaceutically acceptable salt thereof.

15. (new) A compound of formula I



or a pharmaceutically acceptable salt thereof

wherein


R₁ is selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, and CH₂OR₄;

R₂ is selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, heterocyclo or substituted heterocyclo, heteroaryl or substituted heteroaryl, and CH₂OR₄;

R₃ is selected from the group consisting of alkyl or substituted alkyl, and CH₂OR₄;

R₄ and R₄' for each occurrence are each independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, heterocyclo or substituted heterocyclo, and heteroaryl or substituted heteroaryl;

G is selected from the group consisting of:



wherein

R₈ is CN;

R₉, R₁₀ and R₁₁ are each independently selected from the group consisting of hydrogen (H), NO₂, CN, CF₃, OR₄, CO₂R₄, NR₄R₄', CONR₄R₄', CH₂OR₄, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, and heteroaryl or substituted heteraryl;

A to F are each independently selected from N and CR₁;

J, K, L, P and Q are each independently selected from NR₁₂, O, S, SO, SO₂, or CR₁₂R₁₂';

R₁₂ and R₁₂' in each functional group are each independently selected from a bond or R₁,

m is an integer of 0 or 1,

X is a linking group selected from the group consisting of NR_4 and CHR_4 ;

Y is selected from the group consisting of O, NR_4 , NOR_4 , S and CH_2 ;

Z is -O- or NR_4 ; and

n is an integer of 1 or 2;

with the following provisos:

(a) when Y is NOR_4 , R_4 is not hydrogen;

(b) when R_1 is methyl, X is NH, and Y is O or S, then Z is not O;

(c) when


(i) R_1 is methyl,

(ii) X is NH,

(iii) Y is NR_4 ,

(iv) R_4 is selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, and heteroaryl or substituted heteroaryl, and

(v) G has the following structure:



wherein

R_{13} is selected from the group consisting of hydrogen, cyano (-CN), nitro (- NO_2), halo, heterocyclo, OR_{14} , CO_2R_{15} , CONHR_{15} , COR_{15} , $\text{S(O)}_p\text{R}_{15}$, $\text{SO}_2\text{NR}_{15}\text{R}_{15}'$, NHCOR_{15} and $\text{NHSO}_2\text{R}_{15}$;

R_{14} in each functional group is independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, CHF_2 , CF_3 , and COR_{15} ;

R_{15} and R_{15}' in each functional group are each independently selected from the group consisting of hydrogen, alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, heterocycloalkyl or substituted heterocycloalkyl,

arylalkyl or substituted arylalkyl, aryl or substituted aryl, heteroaryl or substituted heteroaryl, and -CN;

AA and BB are each independently selected from the group consisting of hydrogen, halo, cyano(-CN), nitro(-NO₂), alkyl or substituted alkyl, and OR₁₄; and

p is an integer from 0 to 2,

then Z is not O.

16. (new) A pharmaceutical composition comprising the a compound as defined in claim 15, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier therefor.

17. (new) The pharmaceutical composition as defined in claim 16 further comprising a growth promoting agent.

18. (new) A pharmaceutical composition comprising a compound as defined in claim 15, or a pharmaceutically acceptable salt thereof, and at least one additional therapeutic agent selected from the group consisting of parathyroid hormone, bisphosphonates, estrogen, testosterone, progesterone, selective estrogen receptor modulators, growth hormone secretagogues, growth hormone, progesterone receptor modulators, anti-diabetic agents, anti-hypertensive agents, anti-inflammatory agents, anti-osteoporosis agents, anti-obesity agents, cardiac glycosides, cholesterol lowering agents, anti-depressants, anti-anxiety agents, anabolic agents, and thyroid mimetics.

19. (new) A method for treating prostate cancer which comprises administering to a mammalian species in need of treatment an effective amount of a compound as defined in claim 15 or a pharmaceutically acceptable salt thereof.